← Back to Search

Unknown

ABBV-CLS-7262 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Calico Life Sciences LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two weeks
Awards & highlights

Summary

This trial tests how a new drug (ABBV-CLS-7262) interacts with common medications for cholesterol and heart conditions. Participants will take these drugs in different combinations to see how they work together.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~two weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and two weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pharmacokinetics of Digoxin
Pharmacokinetics of Rosuvastatin
Secondary study objectives
Safety and Tolerability

Trial Design

1Treatment groups
Experimental Treatment
Group I: ABBV-CLS-7262Experimental Treatment1 Intervention
ABBV-CLS-7262 + Digoxin + Rosuvastatin
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABBV-CLS-7262
2023
Completed Phase 1
~110

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Calico Life Sciences LLCLead Sponsor
9 Previous Clinical Trials
953 Total Patients Enrolled
AbbVieIndustry Sponsor
1,004 Previous Clinical Trials
513,766 Total Patients Enrolled
~5 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top